| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Gilead's investigational seladelpar shows promise in primary biliary cholangitis | 3 | PMLiVE | ||
| 09.05. | Merck' Keytruda Receives Approval From Health Canada For Biliary Tract Carcinoma In Adults | 219 | AFX News | KENILWORTH (NJ) (dpa-AFX) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved Keytruda, also known as pembrolizumab, for the treatment of adult patients with locally... ► Artikel lesen | |
| 09.05. | Health Canada Approves KEYTRUDA for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy | 1 | CNW | ||
| 25.04. | Compass gains FDA Fast Track status for biliary tract cancer candidate | 1 | Seeking Alpha | ||
| 24.04. | Bilia AB: Bulletin from Bilia's annual general meeting 2024 | 1.636 | GlobeNewswire (Europe) | Bilia AB's AGM took place on Wednesday, 24 April 2024. Adoption of the profit and loss statement and balance sheet The profit and loss statements and the balance sheets of the parent company and the... ► Artikel lesen | |
| 16.04. | AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows | 264 | Benzinga.com | ||
| 16.04. | AstraZeneca shares positive three-year results for Imfinzi combination in biliary tract cancer | 284 | PMLiVE | ||
| 03.04. | Ascletis pulls FXR agonist from pipeline over phase 2 primary biliary cholangitis data | 1 | FierceBiotech | ||
| 02.04. | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer | 122 | PR Newswire | Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC)
Confirmatory... ► Artikel lesen | |
| 20.03. | Biliary Tumor drugs in development, 2023 | 1 | Pharmaceutical Technology | ||
| 12.02. | CymaBay Therapeutics: CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis | 241 | PR Newswire | - FDA has granted Priority Review with a target PDUFA date of August 14 -
NEWARK, Calif., Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused... ► Artikel lesen | |
| 07.02. | Bilia AB: Full-Year Report 1 Jan - 31 Dec 2023 | 268 | GlobeNewswire (Europe) | Stable results in Sweden and Western Europe
Fourth quarter 2023Net turnover amounted to SEK 10,108 M (10,425), a decrease of 3 per cent.Operational earnings amounted to SEK 414 M (574).Sweden and Western... ► Artikel lesen | |
| 05.02. | Tharimmune, Inc.: Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis | 241 | ACCESSWIRE | Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with topline... ► Artikel lesen | |
| 08.01. | Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer | 664 | PR Newswire | HOLON, Israel, Jan. 8, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced... ► Artikel lesen | |
| 19.12.23 | Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion | 285 | JCN Newswire | TOKYO, Dec 19, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF)... ► Artikel lesen | |
| 18.12.23 | Eisai files biliary tract cancer drug tasurgratinib in Japan | 6 | pharmaphorum | ||
| 18.12.23 | CymaBay seeks FDA approval for primary biliary cholangitis therapy | 4 | Pharmaceutical Technology | ||
| 08.12.23 | GENFIT S.A.: GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC) | 345 | GlobeNewswire (Europe) | US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing Authorization... ► Artikel lesen | |
| 27.11.23 | Tharimmune, Inc.: Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis | 251 | ACCESSWIRE | Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerabilityCompany expects to engage FDA on Phase 2 trial design and expects topline... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 6.891 |
| NEL | 4.279 |
| EVOTEC | 3.334 |
| TUI | 1.942 |
| PLUG POWER | 1.727 |
| BAYER | 1.550 |
| SUPER MICRO COMPUTER | 1.471 |
| BIONTECH | 1.404 |
| GAMESTOP | 1.345 |
| RHEINMETALL | 1.168 |
| VOLKSWAGEN | 914 |
| AIXTRON SE | 883 |
| DEUTSCHE BANK | 862 |
| DEUTSCHE LUFTHANSA | 837 |
| SIEMENS ENERGY | 832 |
| BYD | 813 |
| JINKOSOLAR | 809 |
| TESLA | 758 |
| COMMERZBANK | 743 |
| MERCEDES-BENZ | 728 |
| RENK GROUP | 707 |
| THYSSENKRUPP | 692 |
| INFINEON | 681 |
| CUREVAC | 663 |
| BASF | 613 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
